Cargando…

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases

BACKGROUND: Delirium is a highly prevalent disorder among older patients in intensive care units (ICUs). Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Tsutomu, Hashimoto, Kenji
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868039/
https://www.ncbi.nlm.nih.gov/pubmed/20416097
http://dx.doi.org/10.1186/1744-859X-9-18
_version_ 1782181032979595264
author Furuse, Tsutomu
Hashimoto, Kenji
author_facet Furuse, Tsutomu
Hashimoto, Kenji
author_sort Furuse, Tsutomu
collection PubMed
description BACKGROUND: Delirium is a highly prevalent disorder among older patients in intensive care units (ICUs). Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias. Drug treatment for delirium requires careful consideration of the balance between the effective management of symptoms and potential adverse effects. METHODS: We report on five Japanese men (an 84 year old (acute aortic dissociation: Stanford type A), a 55 year old (traumatic subarachnoid hemorrhage and brain contusion), a 76 year old (sepsis by pyelonephritis), an 85 year old (cerebral infarction), and an 86 year old (pulmonary emphysema and severe pneumonia)) in which the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of the patients. RESULTS: Delirium Rating Scale (DRS) scores in these five patients dramatically decreased after treatment with fluvoxamine. CONCLUSION: Doctors should consider fluvoxamine as an alternative approach to treating delirium in ICU patients in order to avoid the risk of side effects and increased mortality from antipsychotic drugs.
format Text
id pubmed-2868039
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28680392010-05-12 Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases Furuse, Tsutomu Hashimoto, Kenji Ann Gen Psychiatry Case report BACKGROUND: Delirium is a highly prevalent disorder among older patients in intensive care units (ICUs). Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias. Drug treatment for delirium requires careful consideration of the balance between the effective management of symptoms and potential adverse effects. METHODS: We report on five Japanese men (an 84 year old (acute aortic dissociation: Stanford type A), a 55 year old (traumatic subarachnoid hemorrhage and brain contusion), a 76 year old (sepsis by pyelonephritis), an 85 year old (cerebral infarction), and an 86 year old (pulmonary emphysema and severe pneumonia)) in which the selective serotonin reuptake inhibitor and sigma-1 receptor agonist fluvoxamine was effective in ameliorating the delirium of the patients. RESULTS: Delirium Rating Scale (DRS) scores in these five patients dramatically decreased after treatment with fluvoxamine. CONCLUSION: Doctors should consider fluvoxamine as an alternative approach to treating delirium in ICU patients in order to avoid the risk of side effects and increased mortality from antipsychotic drugs. BioMed Central 2010-04-24 /pmc/articles/PMC2868039/ /pubmed/20416097 http://dx.doi.org/10.1186/1744-859X-9-18 Text en Copyright ©2010 Furuse and Hashimoto; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case report
Furuse, Tsutomu
Hashimoto, Kenji
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title_full Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title_fullStr Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title_full_unstemmed Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title_short Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
title_sort sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868039/
https://www.ncbi.nlm.nih.gov/pubmed/20416097
http://dx.doi.org/10.1186/1744-859X-9-18
work_keys_str_mv AT furusetsutomu sigma1receptoragonistfluvoxaminefordeliriuminintensivecareunitsreportoffivecases
AT hashimotokenji sigma1receptoragonistfluvoxaminefordeliriuminintensivecareunitsreportoffivecases